Skip to main content
Fig. 1 | International Journal of Retina and Vitreous

Fig. 1

From: Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings

Fig. 1

Median best corrected visual acuity in letters (solid line) and median central macular thickness in μm (dashed line) before the initiation of treatment with ranibizumab (PR), 6 and 3 months before the switch to aflibercept, at the day of the decision to switch and every 3 months after the switch up to 36 months follow-up

Back to article page